1900 Route des Crêtes, BP 313
233 articles with NicOx SA
Nicox SA, an international ophthalmology company, provided business and financial highlights for Q2 2021 for Nicox SA and its subsidiaries as well as an update on its strategy and key expected value-inflection milestones.
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board
Nicox SA, an international ophthalmology company, announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, M.D., Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego, and Sanjay G. Asrani, M.D., Professor of Ophthalmology, Duke University, will be joining the Nicox Glaucoma Clinical Advisory Board.
Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement
Nicox SA, an international ophthalmology company, announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE®, 0.24% in the Chinese and the majority of South East Asian markets.
Nicox SA, an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period.
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial
Nicox SA, an international ophthalmology company, presented results from the Dolomites Phase 2 clinical trial showing that NCX 470, a novel nitric oxide -donating prostaglandin analog, produced significantly greater intraocular pressure lowering effects in glaucoma patients compared with the current standard of care, latanoprost.
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
Nicox SA, an international ophthalmology company, announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA®, 0.024% in the United Arab Emirates.
Nicox SA announced that, more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial. Top-line results are expected to be announced during September 2021.
Nicox SA, an international ophthalmology company, announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATETM, 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico.
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA®(latanoprostene bunod ophthalmic solution), 0.024%in Taiwan and Receives Approval in Qatar
6/4/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
8/27/2018Who made a splash in the biotech world this week? Here are some notable people.
Dr. Navratil will be responsible for leading all of the Company's non-clinical and clinical development activities.
Nicox Highlights VYZULTA Approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives
The company provided an overview yesterday.
Bausch & Lomb and Nicox Announce FDA Approval of VYZULTA (latanoprostene Bunod Ophthalmic Solution), 0.024%
Valeant wholly owned subsidiary, Bausch & Lomb a leading global eye health company, and NicOx SA today announced that the FDA has approved the NDA for VYZULTA.
Nicox updated on its activities and cash balance as of September 30, 2017.
Nicox Enters Research Collaboration With Re-Vana Therapeutics on its Next Generation of Stand-Alone NO-donors in a Novel Sustained Release Ophthalmic Formulation
The deal combines Nicox's next generation of stand-alone nitric oxide-donors with Re-Vana's EyeLief long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of intraocular pressure.
NicOx SA And pSivida Enter Strategic Collaboration Agreement To Develop Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma
NicOx SA Announces Licensing Agreement With Eyevance For Commercialization Of ZERVIATE In The United States